UBS AM’s Avalo Therapeutics AVTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$946K Buy
+61,698
New +$1.14M ﹤0.01% 2582

Other funds holding AVTX

UBS AM's AVTX Position: Q3 2026 in Review

UBS AM opened a new position in Avalo Therapeutics (AVTX) in Q3 2026: 61,698 shares worth $946K. The stake represents ﹤0.01% of the portfolio and ranks #2582 among its holdings.

148 funds tracked by Wall St. Rank hold AVTX as of Q3 2026.

  • UBS AM held 61,698 shares of Avalo Therapeutics worth $946K as of Q3 2026.
  • Avalo Therapeutics was a new UBS AM position in Q3 2026.
  • Avalo Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q3 2026, its #2582 holding.
  • 148 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2026.

Based on UBS AM's 13F filing for Q3 2026, filed 16 Nov 2026.